Magma Partners

Magma Partners is a Santiago-based fund that explicitly bridges the gap between Latin American startups and the US market, with a focus on fintech and health among other categories. Check sizes of $250k to $1M place the firm in the seed range, with the ability to lead small priced rounds or anchor angel-heavy raises. The firm is AI-thematic. The input record cites Oncopadi, a Latin American oncology platform, as a portfolio example.

The firm’s natural fit is with LatAm founders building products with credible US market potential, particularly those targeting US Hispanic populations or building B2B software for US enterprises with LatAm engineering teams. For healthcare founders specifically, the right profile is a team building digital health platforms with cross-border ambitions, including oncology platforms, telehealth networks targeting US Hispanic patients, AI-enabled clinical workflow with US enterprise customers, and health-IT software with cross-border deployment plans. Founders building purely local LatAm consumer health or deep biotech are not the natural target.

Geographically, Magma’s advantage is the Chile-US bridge specifically, with documented relationships in both markets and an understanding of how to structure cross-border holding companies for downstream US capital. For founders contemplating US market entry from a LatAm base, the firm is a thoughtful early partner. For founders without LatAm or US ambitions, the strategic logic is weaker.

The right entry path is a warm intro from a portfolio founder, a regional VC, or a US co-investor. The firm reads partner-led decks and responds to clear cross-border theses. The pitch should lead with the US market wedge (specific Hispanic population segment or specific US enterprise customer profile), the LatAm operational advantage, and a credible follow-on plan that addresses cross-border capital realities.

Caveats. Cross-border venture structures introduce tax, governance, and IP considerations that require deliberate planning; engage experienced cross-border counsel from day one. The firm’s healthcare-specific portfolio depth is moderate; reference calls with health-sector founders, including Oncopadi, are advisable. The check size is moderate; for founders raising larger seeds, Magma should be a participant alongside a real lead. For LatAm-anchored health-tech founders with credible US ambitions, Magma Partners is among the more thoughtful regional partners on cross-border strategy; for purely local or US-only founders, the fit is weaker.